Larotrectinib (Vitrakvi)
Targeted TherapyApproved for: NSCLCBiomarker: NTRK Larotrectinib (Vitrakvi) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Related Research News FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLCClinical Research...